Snake venom toxins (Naja naja, Bungarus caeruleus, Daboia russelii, Echis carinatus)

This target group comprises the complex mixture of toxic proteins and peptides found in the venom of the 'Big Four' venomous snakes of South Asia: the Indian Cobra (Naja naja), Common Krait (Bungarus caeruleus), Russell's Viper (Daboia russelii), and Saw-scaled Viper (Echis carinatus) [WHO, 2023]. These venoms contain a diverse array of bioactive molecules, including phospholipase A2 enzymes, metalloproteinases, serine proteases, and three-finger toxins, which collectively disrupt physiological processes such as neuromuscular transmission, blood coagulation, and tissue integrity [UniProt, 2024]. Envenomation by these species leads to severe clinical manifestations ranging from respiratory paralysis and neurotoxicity (primarily from Naja and Bungarus) to systemic hemorrhage and acute kidney injury (primarily from Daboia and Echis) [PubMed, 2014]. Therapeutic intervention primarily involves the administration of polyvalent antivenom, which contains purified antibodies designed to bind and neutralize these specific toxins [StatPearls, 2023]. Emerging research also explores small-molecule inhibitors targeting specific venom enzymes, such as varespladib for phospholipase A2, to supplement traditional immunotherapy and improve outcomes in remote areas [PubMed, 2020].

Other names

Big Four snake venomsIndian snake venom toxinsSouth Asian snake venom antigensNaja naja venomBungarus caeruleus venomDaboia russelii venomEchis carinatus venom

Neutralization of venom antigens via antibody-mediated binding and clearance (antivenom); competitive inhibition of specific enzymatic toxins such as phospholipase A2 (varespladib) or metalloproteinases (marimastat); and symptomatic management of neurotoxicity via acetylcholinesterase inhibition (neostigmine).